Back to today’s briefing

Story perspectives

Eli Lilly's Weight-Loss Pill Sparks 14% Stock Surge

4/19/2025

45 10

Summary

Story summary

Eli Lilly's groundbreaking oral weight-loss pill, Orforglipron, is making waves in Phase 3 trials, with participants shedding an impressive average of 16 pounds. This convenient alternative to injectables has propelled Eli Lilly's stock up by 14%, signaling a bright future in the booming GLP-1 market and establishing the company as a frontrunner in obesity treatments.

1 of 1

Story summary

Eli Lilly's groundbreaking oral weight-loss pill, Orforglipron, is making waves in Phase 3 trials, with participants shedding an impressive average of 16 pounds. This convenient alternative to injectables has propelled Eli Lilly's stock up by 14%, signaling a bright future in the booming GLP-1 market and establishing the company as a frontrunner in obesity treatments.